Jagsonpal Pharma holds 47th AGM on Sep 18, 2026; declares dividend.
Jagsonpal Pharmaceuticals Limited conducted its 47th AGM on September 18, 2026. Key resolutions included adopting FY26 financial statements, declaring a dividend, and appointing Mr. Anil Kumar Matai as an Independent Director. Voting results are expected within two business days.
The announcement pertains to the standard annual general meeting and does not involve any major new financial information, strategic shifts, or significant corporate actions that would materially impact the company's stock.
The announcement is a routine disclosure of AGM proceedings and does not contain any significantly positive or negative financial or strategic news.
Jagsonpal Pharmaceuticals Limited held its 47th Annual General Meeting (AGM) on Friday, September 18, 2026, conducted via Video Conferencing/Other Audio Visual Means (VC/OAVM). The meeting commenced at 3:30 p.m. IST and concluded at 4:04 p.m. IST.
In the absence of the Chairperson, Mr. Manish Gupta, the Managing Director, was elected as the Chairperson for the proceedings. The AGM agenda included the adoption of Audited Financial Statements for the Financial Year ended March 31, 2026, the declaration of a dividend for the same period, the reappointment of a director retiring by rotation, and the ratification of remuneration for the Cost Auditors. Special business transacted included the approval of Mr. Anil Kumar Matai as an Independent Director.
The company provided shareholders with the facility for remote e-Voting from September 14 to September 17, 2026, and also allowed voting during the AGM. The Chairperson presented the operational and financial performance for FY26, followed by a Q&A session. The voting results on the resolutions are expected to be announced within two working days upon receipt of the Consolidated Scrutiniser's Report.
What to do with a filing like this
Jagsonpal Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under agm. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Jagsonpal Pharmaceuticals Limited. Read the original for the full detail.